Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.

@article{Vakhapova2010NightlyST,
  title={Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.},
  author={Veronika Vakhapova and Eitan Auriel and Arnon Karni},
  journal={Clinical neuropharmacology},
  year={2010},
  volume={33 3},
  pages={151-4}
}
BACKGROUND Approximately 90% of patients with multiple sclerosis (MS) experience spasticity during their lifetime. Tizanidine HCl is an alpha2 adrenergic agonist indicated for treating spasticity due to MS or spinal cord injury. OBJECTIVES To compare the clinical efficacy and safety of once-nightly sublingual versus oral tizanidine HCl (8 mg) or placebo in MS patients with spasticity requiring treatment. METHODS A double-blind, double-dummy, randomized, 3-treatment, 2-way crossover… CONTINUE READING